P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY

• G. Gregory,
• J. Timmerman,
• D. Lavie,
• P. Borchmann,
• A. F. Herrera,
• L. Minuk,
• V. Vucinic,
• P. Armand,
• A. Avigdor,
• R. Gasiorowski,
• Y. Herishanu,
• C. Keane,
• J. Kuruvilla,
• J. Palcza,
• P. Pillai,
• P. Marinello,
• N. A. Johnson

Affiliations

G. Gregory

1 School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia

J. Timmerman

2 UCLA Medical Center, Los Angeles, United States of America

D. Lavie

3 Hadassah Medical Center, Jerusalem, Israel

P. Borchmann

4 University Hospital of Cologne, Cologne, Germany

A. F. Herrera

5 City of Hope, Duarte, United States of America

L. Minuk

6 CancerCare Manitoba, Winnipeg, Canada

V. Vucinic

7 University of Leipzig Medical Center, Leipzig, Germany

P. Armand

8 Dana-Farber Cancer Institute, Boston, United States of America

A. Avigdor

9 Sheba Medical Center, Ramat Gan, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

R. Gasiorowski

10 Concord Hospital, University of Sydney, Concord, Australia

Y. Herishanu

11 Tel Aviv Sourasky Medical Center, Tel Aviv-Yafo, Israel

C. Keane

12 Princess Alexandra Hospital, Brisbane, Australia

J. Kuruvilla

13 Princess Margaret Cancer Centre, Toronto, Canada

J. Palcza

14 Merck & Co., Inc., Kenilworth, United States of America

P. Pillai

14 Merck & Co., Inc., Kenilworth, United States of America

P. Marinello

14 Merck & Co., Inc., Kenilworth, United States of America

N. A. Johnson

15 Jewish General Hospital, Montreal, Canada